水包油纳米乳剂增强了H5N1疫苗在小鼠体内的免疫原性。
An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice.
作者信息
Cao Weiping, Davis William G, Kim Jin Hyang, De La Cruz Juan A, Taylor Andrew, Hendrickson Grant R, Kumar Amrita, Ranjan Priya, Lyon L Andrew, Katz Jacqueline M, Gangappa Shivaprakash, Sambhara Suryaprakash
机构信息
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
出版信息
Nanomedicine. 2016 Oct;12(7):1909-1917. doi: 10.1016/j.nano.2016.04.005. Epub 2016 Apr 23.
Abstract
To enhance the immunogenicity of the Influenza H5N1 vaccine, we developed an oil-in-water nanoemulsion (NE) adjuvant. NE displayed good temperature stability and maintained particle size. More importantly, it significantly enhanced IL-6 and MCP-1 production to recruit innate cells, including neutrophils, monocytes/macrophages and dendritic cells to the local environment. Furthermore, NE enhanced dendritic cell function to induce robust antigen-specific T and B cell immune responses. NE-adjuvanted H5N1 vaccine not only elicited significantly higher and long-lasting antibody responses, but also conferred enhanced protection against homologous clade 1 as well as heterologous clade 2 H5N1 virus challenge in young as well as in aged mice. The pre-existing immunity to seasonal influenza did not affect the immunogenicity of NE-adjuvanted H5N1 vaccine.
摘要
为增强H5N1流感疫苗的免疫原性，我们研发了一种水包油纳米乳剂（NE）佐剂。NE表现出良好的温度稳定性并维持了粒径。更重要的是，它显著增强了IL-6和MCP-1的产生，以募集先天细胞，包括中性粒细胞、单核细胞/巨噬细胞和树突状细胞至局部环境。此外，NE增强了树突状细胞功能，以诱导强烈的抗原特异性T细胞和B细胞免疫反应。NE佐剂H5N1疫苗不仅引发了显著更高且持久的抗体反应，还在年轻和老年小鼠中赋予了针对同源1分支以及异源2分支H5N1病毒攻击的增强保护。对季节性流感的预先存在的免疫力并不影响NE佐剂H5N1疫苗的免疫原性。
相似文献
1
An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice.水包油纳米乳剂增强了H5N1疫苗在小鼠体内的免疫原性。
Nanomedicine. 2016 Oct;12(7):1909-1917. doi: 10.1016/j.nano.2016.04.005. Epub 2016 Apr 23.
2
Combined Intranasal Nanoemulsion and RIG-I Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity to Influenza Virus.联合鼻腔内纳米乳剂和 RIG-I 激活 RNA 佐剂增强流感病毒的黏膜、体液和细胞免疫。
Mol Pharm. 2021 Feb 1;18(2):679-698. doi: 10.1021/acs.molpharmaceut.0c00315. Epub 2020 Jun 15.
3
A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.水包油乳剂佐剂H5N1流感病毒单价疫苗诱导抗体的交叉反应性的系统评价与荟萃分析
Vaccine. 2017 May 31;35(24):3162-3170. doi: 10.1016/j.vaccine.2017.04.029. Epub 2017 May 5.
4
Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.纳米乳剂佐剂的重组 H5 血凝素可保护雪貂免受致病性禽流感病毒的挑战。
Vaccine. 2019 Mar 14;37(12):1591-1600. doi: 10.1016/j.vaccine.2019.02.002. Epub 2019 Feb 19.
5
Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice.含灭活流感病毒和 CpG 寡脱氧核苷酸的乳化纳米颗粒对小鼠的宿主免疫反应有重要影响。
PLoS One. 2010 Aug 19;5(8):e12279. doi: 10.1371/journal.pone.0012279.
6
A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.一项评估佐剂季节性（H5N1）流感疫苗在健康日本成年人中的免疫原性和安全性的 II 期、开放标签、多中心研究。
BMC Infect Dis. 2010 Nov 25;10:338. doi: 10.1186/1471-2334-10-338.
7
Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice.经鼻递送含Protollin佐剂的H5N1疫苗可增强小鼠的全身及黏膜免疫。
Vaccine. 2017 Jun 5;35(25):3318-3325. doi: 10.1016/j.vaccine.2017.05.004. Epub 2017 May 9.
8
Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice.阳离子脂质体-DNA 复合物 (CLDC) 佐剂增强了小鼠对大流行性流感 A H5N1 疫苗的免疫原性和交叉保护效力。
Vaccine. 2012 Jan 5;30(2):254-64. doi: 10.1016/j.vaccine.2011.10.103. Epub 2011 Nov 12.
9
Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.在小鼠中通过口服共同给予表达核蛋白的乳酸乳球菌并佐以霍乱毒素B亚基，对多种流感病毒产生广泛的保护性免疫。
Microb Cell Fact. 2015 Aug 5;14:111. doi: 10.1186/s12934-015-0287-4.
10
Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.储备的大流行前含AS03佐剂的H5N1流感病毒疫苗可在雪貂中对H5N2 2.3.4.4分支病毒攻击提供交叉保护。
Virology. 2017 Aug;508:164-169. doi: 10.1016/j.virol.2017.05.010. Epub 2017 May 26.
引用本文的文献
1
Imiquimod-Loaded Phospholipid-Free Small Unilamellar Vesicles Activate the Tumor Immune Microenvironment to Treat Liver Cancer and Liver Metastases.负载咪喹莫特的无磷脂小单层囊泡激活肿瘤免疫微环境以治疗肝癌和肝转移
Adv Healthc Mater. 2025 Aug;14(22):e2501691. doi: 10.1002/adhm.202501691. Epub 2025 Jun 17.
2
Improvement influenza vaccine immune responses with traditional Chinese medicine and its active ingredients.用中药及其活性成分改善流感疫苗免疫反应。
Front Microbiol. 2023 Mar 7;14:1111886. doi: 10.3389/fmicb.2023.1111886. eCollection 2023.
3
Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy.呈现肿瘤相关MUC1表位的嵌合病毒样颗粒在角鲨烯水包油佐剂存在的情况下可导致产生高滴度的特异性IgG抗体：迈向安全的癌症免疫疗法。
J Nanobiotechnology. 2022 Mar 27;20(1):160. doi: 10.1186/s12951-022-01357-1.
4
Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks.纳米乳剂：配方、表征、生物学命运以及对 COVID-19 和其他病毒爆发的潜在作用。
Colloid Interface Sci Commun. 2021 Nov;45:100533. doi: 10.1016/j.colcom.2021.100533. Epub 2021 Oct 20.
5
Self-Assembled Cationic-Covered Nanoemulsion as A Novel Biocompatible Immunoadjuvant for Antiserum Production Against Scorpion Venom.自组装阳离子包覆纳米乳液作为一种新型生物相容性免疫佐剂用于抗蝎毒抗血清的制备
Pharmaceutics. 2020 Sep 29;12(10):927. doi: 10.3390/pharmaceutics12100927.
6
Nasal delivery of H5N1 avian influenza vaccine formulated with GenJet™ or in vivo-jetPEI induces enhanced serological, cellular and protective immune responses.鼻腔接种用 GenJet™ 或体内喷射聚乙烯亚胺（in vivo-jetPEI）配制的 H5N1 禽流感疫苗可诱导增强的血清学、细胞和保护免疫应答。
Drug Deliv. 2018 Nov;25(1):773-779. doi: 10.1080/10717544.2018.1450909.
7
Vaccine approaches conferring cross-protection against influenza viruses.疫苗接种方法可提供针对流感病毒的交叉保护。
Expert Rev Vaccines. 2017 Nov;16(11):1141-1154. doi: 10.1080/14760584.2017.1379396. Epub 2017 Sep 19.
本文引用的文献
1
Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.罗马尼亚大流行性流感疫苗生产水包油乳剂佐剂制造技术转让：含佐剂裂解病毒灭活H5N1疫苗的临床前评估
Hum Vaccin Immunother. 2016 Apr 2;12(4):1009-26. doi: 10.1080/21645515.2015.1111495. Epub 2015 Nov 30.
2
Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.大流行前A/H5N2流感减毒活候选疫苗在成年志愿者中的临床试验：一项安慰剂对照、随机双盲I期研究的结果
Vaccine. 2015 Sep 22;33(39):5110-7. doi: 10.1016/j.vaccine.2015.08.019. Epub 2015 Aug 19.
3
Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination.水包油乳剂MF59可增强生发中心B细胞分化并提高疫苗接种后的持久性。
J Immunol. 2015 Aug 15;195(4):1617-27. doi: 10.4049/jimmunol.1402604. Epub 2015 Jul 13.
4
Characterization of a novel oil-in-water emulsion adjuvant for swine influenza virus and Mycoplasma hyopneumoniae vaccines.一种用于猪流感病毒和猪肺炎支原体疫苗的新型水包油乳剂佐剂的特性研究
Vaccine. 2015 Jun 9;33(25):2903-8. doi: 10.1016/j.vaccine.2015.04.065. Epub 2015 Apr 28.
5
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.用于大流行疫苗接种准备的流感 H5N1 疫苗和 MF59 佐剂的即时混合：抗体反应和安全性。一项 1 期临床试验。
Open Forum Infect Dis. 2014 Nov 18;1(3):ofu102. doi: 10.1093/ofid/ofu102. eCollection 2014 Dec.
6
Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant.含或不含 AS03 佐剂的灭活单价流感 A(H5N1)病毒疫苗的安全性、反应原性和免疫原性。
Open Forum Infect Dis. 2014 Oct 8;1(3):ofu091. doi: 10.1093/ofid/ofu091. eCollection 2014 Dec.
7
Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.AS03 佐剂 H5N1 大流行前流感疫苗在 3 至 9 岁儿童中的 II 期、随机、开放、对照研究：接种后 24 个月的安全性和免疫原性持久性随访。
Influenza Other Respir Viruses. 2015 Mar;9(2):68-77. doi: 10.1111/irv.12295. Epub 2015 Feb 5.
8
The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study.一种MF59佐剂H5N1大流行前流感疫苗在接种同源或异源H5N1疫苗的健康成年人中的安全性和免疫原性：一项观察性研究。
BMC Infect Dis. 2014 Nov 14;14:587. doi: 10.1186/s12879-014-0587-z.
9
AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.6个月至17岁儿童使用AS03B佐剂H5N1流感疫苗：一项2/3期随机、安慰剂对照、观察者盲法试验。
J Infect Dis. 2015 Mar 1;211(5):801-10. doi: 10.1093/infdis/jiu548. Epub 2014 Oct 6.
10
Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.在一项针对 65 岁及以上成年人的随机试验中，三价流感疫苗与 AS03 佐剂联合使用可诱导出更强的抗原特异性 CD4+ T 细胞应答。
BMC Infect Dis. 2014 Jul 30;14:425. doi: 10.1186/1471-2334-14-425.
Zotero 插件